Tarsus Pharmaceuticals, Inc.
TARS· Nasdaq
Released Nov 13, 2024, after the close
10-Q filed Nov 13, 2024, 44 days after period end · 0001819790-24-000129
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $48.12M | $1.87M | $0.00 | $1.24M |
| Net Income | -$23.42M | -$39.15M | -$22.51M | -$15.70M |
| EPS Diluted |
Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR
| -$0.61 |
| -$1.28 |
| -$0.84 |
| -$0.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.